Felicia Coleman
Psychiatric/Mental Health · Longview, TXNPI 1609132521
Payments from drug & device makers
Across 494 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$1K
- AbbVie$820
- Otsuka America Pharmaceutical, Inc.$762
- plus $3K from 14 others
What the payments were for
- Food & beverage$9,37399%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 75 | $1,564 |
| Teva Pharmaceuticals USA, Inc. | 96 | $1,437 |
| Vanda Pharmaceuticals Inc. | 64 | $1,303 |
| Alkermes, Inc. | 52 | $1,070 |
| AbbVie | 51 | $820 |
| Otsuka America Pharmaceutical, Inc. | 37 | $762 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $704 |
| E.r. Squibb & Sons, L.L.C. | 22 | $349 |
| Lundbeck LLC | 16 | $286 |
| Supernus Pharmaceuticals, Inc. | 14 | $241 |
| Axsome Therapeutics, Inc. | 9 | $219 |
| Idorsia Pharmaceuticals US Inc | 10 | $201 |
| Johnson & Johnson | 8 | $150 |
| Indivior Inc. | 5 | $110 |
| OWP Pharmaceuticals, Inc. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Merck | 2 | $45 |
| Noven Therapeutics, LLC | 2 | $32 |
| Sage Therapeutics, LLC | 2 | $31 |
| Braeburn Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,479 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 24 | $33,281 |
| RexultiBrexpiprazole | 18 | $29,511 |
| TrintellixVortioxetine Hydrobromide | 14 | $7,634 |
| Quetiapine Fumarate | 51 | $1,195 |
| Oxcarbazepine | 18 | $819 |
| Haloperidol Decanoate | 18 | $681 |
| Olanzapine | 26 | $678 |
| Aripiprazole | 29 | $564 |
| Hydroxyzine Hcl | 13 | $504 |
| Haloperidol | 12 | $417 |
| Buspirone Hcl | 21 | $359 |
| Mirtazapine | 15 | $325 |
| Clonazepam | 41 | $324 |
| Lamotrigine | 28 | $309 |
| Hydroxyzine Pamoate | 18 | $281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $820 | $33,28124 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $762 | $29,51118 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $56 | $7,63414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Longview
- Tracy HicksLongview$684K
- Tracy TaylorLongview$14K
- Wendy RogersLongview$13K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.